Chemotherapy Induced Peripheral Neuropathy Treatment Market
完整報告名稱與涵蓋範圍
Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Pharmacological (Anticonvulsants, Antidepressants, Analgesics, Topical Agents), Non Pharmacological Treatments), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, and Segment Forecasts, 2026-2035
報告摘要
Chemotherapy induced peripheral neuropathy treatment addresses the sensory and motor nerve damage caused by neurotoxic regimens built on platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide. Because no therapy is approved specifically to reverse the condition, the market is defined by symptom-directed management: duloxetine as the best-supported option for painful neuropathy, gabapentinoids and tricyclic antidepressants used off label, topical capsaicin and compounded analgesic preparations, and a growing complement of non-pharmacological approaches including scrambler-type neuromodulation, limb cryotherapy and compression during infusion, exercise programs, and acupuncture.
Demand expands with cancer survivorship itself. Longer survival on taxane and platinum regimens leaves a widening population living with chronic numbness, pain, and fall risk, and oncology guidelines now instruct clinicians to assess neuropathy at every visit, which formalizes treatment initiation. The most important structural dynamic is the pipeline: clinical programs pursuing nerve-protective and nerve-regenerative mechanisms could convert a largely generic, off-label category into a branded prevention market. Payer willingness to cover neuromodulation devices and cryocompression systems is a second swing factor.
North America generates the largest revenue given high chemotherapy volumes, survivorship program infrastructure, and duloxetine guideline adoption, while Asia Pacific growth follows the rapid expansion of cancer treatment capacity in China and India. Competition is fragmented across generic drug manufacturers, a small group of device makers, and development-stage biotechnology companies.
The InsightAce study presents revenue forecasts in US$ across all treatment type, distribution channel, and regional segments for 2026-2035, with segment trend analysis, competitive landscape assessment, and company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Snapshot
Chapter 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Treatment Type Estimates & Trend Analysis
5.1. Treatment Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Treatment Type:
5.2.1. Anticonvulsants
5.2.2. Antidepressants
5.2.3. Analgesics
5.2.4. Topical Agents
5.2.5. Non Pharmacological Treatments
Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis
6.1. Distribution Channel & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
6.2.1. Hospital Pharmacies
6.2.2. Retail Pharmacies
6.2.3. Online Pharmacies
Chapter 7. Chemotherapy Induced Peripheral Neuropathy Treatment Market: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. United States
7.1.2. Canada
7.2. Europe
7.2.1. Germany
7.2.2. United Kingdom
7.2.3. France
7.2.4. Italy
7.2.5. Spain
7.2.6. Rest of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. Japan
7.3.3. India
7.3.4. South Korea
7.3.5. Australia
7.3.6. Southeast Asia
7.3.7. Rest of Asia Pacific
7.4. Latin America
7.4.1. Brazil
7.4.2. Mexico
7.4.3. Rest of Latin America
7.5. Middle East & Africa
7.5.1. GCC Countries
7.5.2. South Africa
7.5.3. Rest of Middle East & Africa
Chapter 8. Competitive Landscape
8.1. Company Market Positioning Analysis
8.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 9. Company Profiles
9.1. Pfizer
9.2. Eli Lilly and Company
9.3. Viatris
9.4. Teva Pharmaceutical Industries
9.5. Sun Pharmaceutical Industries
9.6. Cipla
9.7. Dr. Reddy's Laboratories
9.8. Grunenthal (Averitas Pharma)
9.9. Assertio Holdings
9.10. WinSanTor
9.11. NeuroMetrix
9.12. Paxman
圖表清單 List of Tables & Figures
Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Treatment Type, 2026-2035 (US$ Mn)
Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation Overview
Table 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 2. Global Market Share by Treatment Type, 2026 & 2035
Table 3. Pharmacological versus Non Pharmacological Treatment Revenue Comparison, 2026-2035 (US$ Mn)
Figure 3. Cancer Survivorship and Neuropathy Prevalence Trend Analysis
Table 4. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Global Market Share by Distribution Channel, 2026 & 2035
Table 5. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Neuroprotective Pipeline Candidate Landscape by Development Phase
Table 6. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Growth Opportunity Analysis
Table 7. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Neuromodulation and Cryocompression Device Adoption Outlook
Table 8. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Market Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們